Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML2673

Sigma-Aldrich

Deferasirox

≥98% (HPLC)

Sinônimo(s):

4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

10 MG
R$ 742,00
50 MG
R$ 3.003,00

R$ 742,00

Check Cart for Availability
Solicite uma grande encomenda
Todas as fotos(1)

Selecione um tamanho

Alterar visualização
10 MG
R$ 742,00
50 MG
R$ 3.003,00

About This Item

Fórmula empírica (Notação de Hill):
C21H15N3O4
Número CAS:
201530-41-8
Peso molecular:
373.36
Número MDL:
MFCD09951804
Código UNSPSC:
12352200
NACRES:
NA.77

R$ 742,00

Check Cart for Availability
Solicite uma grande encomenda

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O

InChI

1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+

chave InChI

FMSOAWSKCWYLBB-VBGLAJCLSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.[1]

Ações bioquímicas/fisiológicas

Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.[2]
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator

Pictogramas

Exclamation markEnvironment
GHS07,GHS09

Palavra indicadora

Warning

Frases de perigo

H302,H400

Declarações de precaução

P273 - P301 + P312 + P330

Classificações de perigo

Acute Tox. 4 Oral - Aquatic Acute 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000245905
0000245905
0000198000
0000183094
0000154816

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Kangna Cao et al.
European journal of clinical pharmacology, 76(1), 51-59 (2019-11-05)
Our aim was to evaluate the influence of genetic polymorphisms involved in the metabolism and transportation of deferasirox on deferasirox pharmacokinetics in the Chinese population. Thirty-eight healthy Chinese subjects were administered with a single dose of 20 mg kg-1 deferasirox.
Goldie Y L Lui et al.
Oncotarget, 6(22), 18748-18779 (2015-07-01)
Newer and more potent therapies are urgently needed to effectively treat advanced cancers that have developed resistance and metastasized. One such strategy is to target cancer cell iron metabolism, which is altered compared to normal cells and may facilitate their
Omid Reza Zekavat et al.
Journal of pediatric hematology/oncology, 43(1), e26-e28 (2020-09-15)
This study was performed on patients with transfusion-dependent beta-thalassemia (TDT) to investigate the effect of HFE gene mutations of iron overload in a large group of patients with TDT major and its relationship with heart and liver T2* magnetic resonance
Abbas Rahdar et al.
Life sciences, 270, 119146-119146 (2021-02-06)
Deferasirox (DFX) was formulated into oil-in-water microemulsions in the presence of pluronicto improve its oral bioavailability. The size of the DFX-loadedmicroemulsions system measured by dynamic light scattering (DLS) was about 9 nm. The anti-proliferative and anti-lipid peroxidation effects of DFX and
Nesma Ahmed Safwat et al.
Pediatric research, 89(1), 185-190 (2020-06-17)
The genetic variants of the receptor for advanced glycation end products (RAGE) gene have been associated with vascular disease risk. The objective of this work was to explore the association of three single-nucleotide polymorphisms (SNPs) of RAGE gene (374T/A, 429T/C
Exibir todos os documentos relacionados

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica